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ABSTRACT
Neuroleptic malignant syndrome is a neurological emergency caused by dysregulation of dopaminergic neurotransmission. While it is 
typically characterized by muscle rigidity, fever and altered mental status, it may have a heterogeneous and non-specific presentation, 
leading to delays in diagnosis and treatment. Treatment involves cessation of dopamine-receptor antagonists and supportive mea-
sures, but in more severe cases, bromocriptine, dantrolene, benzodiazepines and/or electroconvulsive therapy should be considered. 
We present the case of a 66-year-old man with severe neuroleptic malignant syndrome, diagnosed due to need for continuous invasive 
ventilation in an Intensive Care Unit, after successful treatment for respiratory sepsis. The patient recovered after electroconvulsive 
therapy and administration of bromocriptine. This unusually severe case illustrates the need for a high level of suspicion for neuroleptic 
malignant syndrome in critically ill patients with malignant catatonic syndromes, allowing for an early diagnosis and potentially life-
saving treatment. 
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RESUMO
A síndrome maligna dos neurolépticos é uma emergência neurológica causada pela desregulação da neurotransmissão dopami-
nérgica. Apesar de habitualmente caracterizada por rigidez muscular, febre e alteração do estado mental, pode apresentar-se de 
forma inespecífica e heterogénea, atrasando o diagnóstico e tratamento. O tratamento engloba a interrupção de antagonistas dos 
receptores dopaminérgicos, medidas de suporte e, em casos mais graves, bromocriptina, dantroleno, benzodiazepinas e/ou terapia 
electroconvulsiva. Neste artigo descrevemos o caso clínico de um homem de 66 anos com síndrome maligna dos neurolépticos grave, 
diagnosticada devido à necessidade de ventilação artificial continuada na Unidade de Cuidados Intensivos, após tratamento de uma 
sépsis respiratória. O doente melhorou significativamente após terapia electroconvulsiva e administração de bromocriptina. Este caso, 
de gravidade particular, sublinha a necessidade de manter um elevado nível de suspeita de síndrome maligna dos neurolépticos em 
doentes em estado crítico com síndromes catatónicos malignos, permitindo assim um diagnóstico precoce e tratamento dirigido.
Palavras-chave: Síndrome Maligna dos Neurolépticos/diagnóstico; Síndrome Maligna dos Neurolépticos/tratamento; Unidades de 
Cuidados Intensivos
INTRODUCTION
 Neuroleptic malignant syndrome (NMS) is a neurological emergency caused by marked dysregulation of dopamin-
ergic neurotransmission, usually following the administration of dopamine-receptor antagonists or sudden withdrawal of 
dopamine-receptor agonists.1 While it is typically characterized by rigidity, fever and altered mental status,2 NMS may have 
a heterogeneous and non-specific presentation, requiring cautious exclusion of other medical conditions.1 Consequently, 
diagnosis is frequently masked and delayed, contributing to the high mortality rate associated with this condition (currently 
around 14%).2 Treatment includes discontinuation of dopamine-receptor antagonists, supportive measures and, in more 
severe cases, administration of bromocriptine,3 benzodiazepines, dantrolene4 and/or electroconvulsive therapy (ECT).5 We 
present the case of a 66-year-old man with unusually severe NMS, diagnosed due to the need for continuous invasive ven-
tilation in an Intensive Care Unit (ICU) after successful treatment of respiratory sepsis, and who recovered after a course 
of ECT and treatment with bromocriptine.
CASE REPORT
 A 66-year-old man with prior diagnosis of schizophrenia was admitted to an ICU due to respiratory infection and septic 
shock syndrome, evolving rapidly to stupor and respiratory failure, and requiring sustained sedation for orotracheal intuba-
tion. At admission, all psychiatric medication was discontinued, and a course of empirical antibiotic treatment was start-
ed. Three days later, upon improvement of respiratory function and laboratory parameters, propofol was interrupted and 
the patient was extubated. However, leukocytosis and mild elevations of lactate dehydrogenase and liver transaminases 
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persisted, despite normal creatine kinase levels. In the following days, generalized tremor and marked rigidity was noted, 
and the patient developed sustained autonomic nervous dysfunction, with tachycardia (up to 117 bpm), unstable blood 
pressure (systolic: 130 - 163 mmHg; diastolic: 67 - 82 mmHg), diaphoresis, fever (up to 38.6º C) and diarrhea. Rapid dete-
rioration of respiratory function with accumulation of respiratory secretions and ineffective cough reflex led to re-intubation 
and prompted a new course of empirical antibiotic treatment. Despite full resolution of the respiratory infection, motor and 
autonomic abnormalities persisted and weaning of invasive ventilation proved impossible, prompting a liaison consultation 
with both Neurology and Psychiatry. 
 Psychiatric assessment, review of medical records and family interview revealed that he had been diagnosed with 
schizophrenia at the age of 40 but had never complied with treatment. However, five months prior to the current episode, 
the patient had been admitted to a psychiatric inpatient unit and had started, for the first time, continued treatment with 
haloperidol (15 mg/day), clozapine (100 mg/day) and flurazepam (15 mg/day). Except for childhood epilepsy, with no 
known manifestations or treatment since adolescence, medical history was unremarkable, as was family neuropsychiatric 
history. On examination, the patient was mostly uncooperative, responding only occasionally with yes-no answers using 
eye-blinks or finger movements. Waxy flexibility and catatonic posturing were noted (Video 1). Brain CT and MRI, EEG, 
cerebral-spinal fluid examination and cultures were unremarkable, and catatonia due to a medical condition, or NMS, were 
considered. Formal assessment revealed a Bush-Francis Catatonia Rating Scale (BFCRS) score of 23, making it impos-
sible to perform other clinical assessments, including the Montreal Cognitive Assessment Scale (MoCA). 
 Since all neuroleptics had been interrupted previously, and supportive measures were fully in place, treatment was 
started with lorazepam (2.5 to 5 mg/day), with no clear benefit. At this moment, ECT was offered and accepted by the pa-
tient and family. A course of twice weekly, bitemporal, brief-pulse ECT was thus started on day 26 after admission, under 
propofol (50 to 120 mg/session) and succinylcholine (50 to 75 mg/session). After four sessions, the patient had improved 
sufficiently to be extubated (Video 2), and after 11 treatments, given the stability of clinical response, with a 65,2% reduc-
tion in the BFRCS (score = 8), ECT was interrupted. Bromocriptine was then started and titrated to 15 mg/day, resulting in 
further improvement, with most catatonic symptoms subsiding (BFCRS score = 1) and a MoCA score of 11 (Video 3).
DISCUSSION
 NMS is a life-threatening condition with a challenging diagnosis and treatment. Decreased dopamine D2 receptor 
activity within the nigrostriatal, hypothalamic and mesolimbic/cortical pathways has been proposed to explain the clinical 
triad that typically characterizes this syndrome, namely, rigidity, fever and altered mental status.6,7 However, patients may 
also present with minor manifestations, namely tachycardia, abnormal arterial pressure, tachypnea, diaphoresis and leu-
kocytosis.8 Differential diagnosis is particularly difficult since several non-psychiatric conditions may present with similar 
features, and the clinical picture can easily be misinterpreted as a reflection of other primary psychiatric conditions.1  In the 
case described here, the patient presented with unusually severe major and minor manifestations of NMS, requiring con-
tinued invasive ventilation in the ICU due to ineffective cough reflex and accumulation of respiratory secretions. However, 
the existence of a previous infectious condition and the persistence of symptoms several weeks after the interruption of 
antipsychotic medication masked and delayed the diagnosis. In all suspected NMS cases, a careful review of medication 
is mandatory, and all dopamine-receptor antagonists should be immediately discontinued. Patients should be admitted 
to an ICU and supportive measures should be started.1 If an insufficient response is obtained, other measures should be 
considered, namely bromocriptine, dantrolene,3 benzodiazepines4 and/or ECT.5 ECT may be used as first line treatment, 
particularly when the condition is considered to be potentially life-threatening.9  It is a low-risk intervention that prompts 
significant clinical improvement within a short time-interval, with the additional advantage of allowing treatment of catatonia 
due to other causes, namely catatonia that is secondary to another medical condition or to a mental disorder. Indeed, ECT 
seems to be effective in all forms of catatonia, which is particularly useful when the underlying cause is unknown.10
 We previously reported the case of a 44-year-old woman with no relevant psychiatric history that was admitted due to 
metabolic encephalopathy secondary to acute renal failure and developed severe NMS after the administration of antip-
sychotics. The patient improved after interruption of antipsychotics, followed by ECT and administration of a dopamine-
receptor agonist.11 Here, ECT also resulted in significant improvement, with additional gains after introduction of bromocrip-
tine, further supporting the diagnosis of NMS, rather than catatonia due to a mental disorder or medical condition.12 In both 
cases, diagnosis was delayed mainly because the clinical manifestations of NMS were recurrently attributed to other, previ-
ously diagnosed, systemic conditions. This unusually severe case thus illustrates the need for a high level of suspicion for 
NMS in critically ill patients with malignant catatonic syndromes, allowing for an early diagnosis and potentially life-saving 
treatment.
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Figure 3 – Finger nose test (0 to 15 seconds); Tying his shoes (15 to 30 seconds); Visiting the inpatients unit after discharge (30 to 50 
seconds); (see Video 3: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13029/Video_03.mp4)
